Article

High expression of WT1 gene in acute myeloid leukemias with more predominant WT1+17AA isoforms at relapse

Department of Hematology, The First People's Hospital of Changzhou, Third Affiliated to Suzhou University, Changzhou, China.
Leukemia research (Impact Factor: 2.69). 05/2009; 34(1):46-9. DOI: 10.1016/j.leukres.2009.04.004
Source: PubMed

ABSTRACT Real-time quantitative reverse transcriptase polymerase chain reaction method was established for detecting the expression levels of WT1 gene and WT1+17AA isoforms in 226 acute myeloid leukemia (AML) bone marrow (BM) cells. The results showed that WT1 gene was 2-3 logarithms expressed more in AML BM cells at initial diagnosis or relapse than in normal BM cells (p<0.001), with predominant WT1+17AA isoforms expression (the ratio of WT1+17AA/WT1 more than 0.50). Interestingly the ratio of WT1+17AA/WT1 was statistically higher in relapsed AMLs than in initially diagnosed (p=0.01), speculating that WT1+17AA isoforms might participate in AML relapse.

0 Followers
 · 
82 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Relapse is the major cause of treatment failure after allogeneic hematopoietic cell transplantation (alloHCT) for acute leukemia and myelodysplastic syndrome (MDS). Wilms' tumor Ag (WT1) is overexpressed in the majority of acute leukemia and MDS patients and has been proposed as a universal diagnostic marker for detection of impending relapse. Comprehensive studies have shown that WT1 transcript levels have predictive value in acute leukemia patients in CR after chemotherapy. However, the focus of this study is the period after alloHCT for predicting relapse onset. We analyzed the accumulation of WT1 mRNA transcripts in PB of 82 leukemia and MDS patients and defined specific molecular ratios for relapse prediction. The extensively validated WT1/c-ABL ratio was used to normalize increases in WT1 transcript levels. The observed lead time of crossing or exceeding set WT1 levels is presented along with linear interpolation to estimate the calculated day the WT1 thresholds were crossed. The WT1/c-ABL transcript ratio of 50 or above yielded 100% specificity and 75% sensitivity reliably predicting future relapse with an observed average of 29.4 days (s.d.=19.8) and a calculated average of 63 days (s.d.=29.3) lead time before morphologic confirmation. A lower ratio of 20 or above gave lower specificity, but higher sensitivity (84.8% and 87.5%, respectively) identified more patients who relapsed, at earlier times, providing an earlier warning with actual average lead time of 49.1 days (s.d.=30.8) and calculated average of 78 days (s.d.=28.8). WT1 transcript levels serve as a diagnostic relapse test with greater sensitivity than the morphologic approach used in the clinic as a readout.Bone Marrow Transplantation advance online publication, 22 September 2014; doi:10.1038/bmt.2014.209.
    Bone Marrow Transplantation 09/2014; 50(1). DOI:10.1038/bmt.2014.209 · 3.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Wilms' tumor (WT1) gene overexpresses in leukemic cells which is alternatively spliced at two sites, yielding four isoforms: WT1 (+/+), (+/-), (-/+), and (-/-). Curcumin is one of major active components of the spice turmeric, widely known as anticancer. This study investigated the effects and inhibitory mechanism of pure curcumin on WT1 isoform-transfected U937 cells. WT1 transfected U937 cells were initially treated for 24 h, with 10 µM pure curcumin. Pure curcumin exhibited a strong inhibitory effect on WT1 (+/+) mRNA level detected by real time PCR. Treatment of WT1 transfected U937 cells with non-cytotoxic doses (10, 15, and 17 µM) of pure curcumin decreased WT1 protein levels in a dose-dependent manner. Pure curcumin at the concentration of 15 µM significantly decreased the protein levels of the WT (+/+) isoform in a time-dependent manner. It also decreased exogenous WT1 (+/+) protein half-life. WT1 protein expression was inhibited by protein kinase C inhibitor (GF109203x) suggesting that pure curcumin decreased exogenous WT1 (+/+) expression in transfected U937 cells via protein kinase C during post-translational processing.
  • [Show abstract] [Hide abstract]
    ABSTRACT: WT1 plays a dual role in leukemia development, probably due to an imbalance in the expression of the 4 main WT1 isoforms. We quantify their expression and evaluate them in a series of AML patients. Our data showed a predominant expression of isoform D in AML, although in a lower quantity than in normal CD34+ cells. We found a positive correlation between the total WT1 expression and A, B and C isoforms. The overexpression of WT1 in AML might be due to a relative increase in A, B and C isoforms, together with a relative decrease in isoform D expression.
    Leukemia research 10/2013; DOI:10.1016/j.leukres.2013.10.009 · 2.69 Impact Factor